NEUROLOGY / BASIC RESEARCH
miR-93-5p attenuates apoptosis and autophagy by regulating SRY-box2 in spinal cord-injured rats in vivo and PC12 cells in vitro
More details
Hide details
1
Department of Spine Surgery, Beijing Jishuitan Hospital, Beijing, China
Submission date: 2020-03-29
Final revision date: 2020-06-21
Acceptance date: 2020-07-06
Online publication date: 2020-08-14
Publication date: 2026-04-30
Corresponding author
Da He
Department
of Spine Surgery
Beijing Jishuitan Hospital
Beijing 100035
China
Arch Med Sci 2026;22(2):1119-1129
KEYWORDS
TOPICS
ABSTRACT
Introduction:
In the current work we studied the involvement of miR-93-5p in spinal cord injury (SCI) by involving SCI rats and LPS-mediated injuries in PC12 cells.
Material and methods:
The PC12 cells were exposed to LPS in order to induce cell injury that mimicked the in vitro model of spinal cord injury. The in vivo model was created by submitting rats to contusion injury. The cell apoptosis and viability were evaluated by flow cytometry and cell counting kit (CCK-8). The expression of various apoptosis and autophagy-related proteins was done by western blot assay.
Results:
The treatment of LPS caused cell injuries in PC12 cells. The levels of miR-93-5p were suppressed in LPS-injured cells. Over-expression of miR-93-5p decreased autophagy and apoptosis and increased cell viability in LPS injured cells via up-regulation of SRY-box2. Up-regulation of SRY-box2 ameliorated LPS-mediated cell injury whereas suppression of SRY-box2 accelerated the LPS-mediated cell injury. Also, upregulation of miR-93-5p blocked the JAK/STAT and MAPK/ERK pathways via up-regulating the expression of SRY-box2. Treatment in SCI rats with miR-93-5p agomir inhibited cell apoptosis and autophagy.
Conclusions:
The results of the study confirmed the attenuating role of miR-93-5p against cell autophagy and apoptosis in LPS-injured PC12 cells and SCI rats via up-regulation of the expression of SRY-box2.
REFERENCES (36)
1.
Lee BB, Cripps RA, Fitzharris M, Wing PC. The global map for traumatic spinal cord injury epidemiology: update 2011, global incidence rate. Spinal Cord 2014; 52: 110-6.
2.
Yunta M, Nieto-Díaz M, Esteban FJ, Caballero-López M, Navarro-Ruíz R, Reigada D. MicroRNA dysregulation in the spinal cord following traumatic injury. PLoS One 2012; 7: e34534.
3.
Nieto-Diaz M, Esteban FJ, Reigada D, Muñoz-Galdeano T, Yunta M, Caballero-López M. MicroRNA dysregulation in spinal cord injury: causes, consequences and therapeutics. Front Cell Neurosci 2014; 8: 53.
4.
Ning B, Gao L, Liu RH, Liu Y, Zhang NS, Chen ZY. Micro-RNAs in spinal cord injury: potential roles and therapeutic implications. Int J Biol Sci 2014; 10: 997-1006.
5.
Bareyre FM, Schwab ME. Inflammation, degeneration and regeneration in the injured spinal cord: insights from DNA microarrays. Trends Neurosci 2003; 26: 555-63.
6.
Nesic O, Svrakic NM, Xu GY, et al. DNA microarray analysis of the contused spinal cord: Effect of NMDA receptor inhibition. J Neurosci Res 2002; 68: 406-23.
7.
Krichevsky AM. MicroRNA profiling: from dark matter to white matter, or identifying new players in neurobiology. Sci World J 2007; 7: 155-66.
8.
Li Z, Yu X, Shen J, Law PTY, Chan MTV, Wu WKK. MicroRNA expression and its implications for diagnosis and therapy of gallbladder cancer. Oncotarget 2015; 6: 13914-21.
9.
Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2008; 19: 92-105.
10.
Hu JZ, Huang JH, Zeng L, Wang G, Cao M, Lu HB. Anti-apoptotic effect of microRNA-21 after contusion spinal cord injury in rats. J Neurotrauma 2013; 30: 1349-60.
11.
Deng Z, Qian J, Liu FQ, et al. Expression level of miR-93 in formalin-fixed paraffin-embedded tissues of breast cancer patients. Genet Test Mol Biomark 2014; 18: 366-70.
12.
Kawano M, Tanaka K, Itonaga I, Ikeda S, Iwasaki T, Tsumura H. microRNA-93 promotes cell proliferation via targeting of PTEN in osteosarcoma cells. J Exp Clin Cancer Res 2015; 34: 76.
13.
Liang H, Wang F, Chu D, et al. miR-93 functions as an oncomiR for the downregulation of PDCD4 in gastric carcinoma. Sci Rep 2016; 6: 23772.
14.
Fang L, Du WW, Yang W, et al. MiR-93 enhances angiogenesis and metastasis by targeting LATS2. Cell Cycle 2012; 11: 4352-65.
15.
Lattanzi A, Gentner B, Corno D, et al. Dynamic activity of miR-125b and miR-93 during murine neural stem cell differentiation in vitro and in the subventricular zone neurogenic niche. PLoS One 2013; 8: e67411.
16.
Zhang H, Wu F, Kong X, et al. Nerve growth factor improves functional recovery by inhibiting endoplasmic reticulum stress-induced neuronal apoptosis in rats with spinal cord injury. J Transl Med 2014; 12: 130.
17.
Li R, Yin F, Guo YY, Zhao KC, Ruan Q, Qi YM. Knockdown of ANRIL aggravates H2O2-induced injury in PC-12 cells by targeting microRNA-125a. Biomed Pharmacother 2017; 92: 952.
18.
Zhou Y, Cui Z, Xia X, et al. Matrix metalloproteinase-1 (MMP-1) expression in rat spinal cord injury model. Cell Mol Neurobiol 2014; 34: 1151-63.
19.
Liebscher T, Schnell L, Schnell D, et al. Nogo A antibody improves regeneration and locomotion of spinal cord-injured rats. Ann Neurol 2005; 58: 706-19.
20.
Hutchison ER, Okun E, Mattson MP. The therapeutic potential of microRNAs in nervous system damage, degeneration, and repair. Neuromolecular Med 2009; 11: 153-61.
21.
Nakanishi K, Nakasa T, Tanaka N, et al. Responses of microRNAs 124a and 223 following spinal cord injury in mice. Spinal Cord 2010; 48: 192-6.
22.
An Y, Li J, Yuan Q, Fan M. MicroRNA-466c-3p exerts protective effect on neuronal apoptosis and improves functional recovery post spinal cord injury via mitochondrial apoptotic pathway. AMB Expr 2010; 10: 113.
23.
Hao J, Jin X, Shi Y. Zhang H. miR-93-5p enhance lacrimal gland adenoid cystic carcinoma cell tumorigenesis by targeting BRMS1L. Cancer Cell Int 2018; 18: 72.
24.
Fabbri E, Montagner G, Bianchi N, et al. MicroRNA miR-93-5p regulates expression of IL-8 and VEGF in neuroblastoma SK-N-AS cells. Oncol Rep 2016; 35: 2866-72.
25.
Li R, Jin Y, Li Q, Sun X, Zhu H, Cui H. MiR-93-5p targeting PTEN regulates the NMDA-induced autophagy of retinal ganglion cells via AKT/mTOR pathway in glaucoma. Biomed Pharmacother 2018; 100: 1-7.
26.
Gubbay J, Collignon J, Koopman P, et al. A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature 1990; 346: 245-50.
27.
Pevny LH, Nicolis SK. Sox2 roles in neural stem cells. Int J Biochem Cell Biol 2010; 42: 421-4.
28.
Episkopou V. SOX2 functions in adult neural stem cells. Trends Neurosci 2005; 28: 219-21.
29.
Miyagi S, Masui S, Niwa H, et al. Consequence of the loss of Sox2 in the developing brain of the mouse. FEBS Lett 2008; 582: 2811-5.
30.
Jiang J, Li Z, Yu C, Chen M, Tian S, Sun C. MiR-1181 inhibits stem cell-like phenotypes and suppresses SOX2 and STAT3 in human pancreatic cancer. Cancer Lett 2015; 356: 962-70.
31.
Kim NH, Lee MY, Park SJ, Choi JS, Oh MK, Kim IS. Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3. Immunology 2007; 122: 607-14.
32.
Tsuda M, Kohro Y, Yano T, et al. JAK-STAT3 pathway regulates spinal astrocyte proliferation and neuropathic pain maintenance in rats. Brain 2011; 134: 1127-39.
33.
Yamauchi K, Osuka K, Takayasu M, et al. Activation of JAK/STAT signalling in neurons following spinal cord injury in mice. J Neurochem 2006; 96: 1060-70.
34.
Xu Z, Wang BR, Wang X, et al. ERK1/2 and p38 mitogen-activated protein kinase mediate iNOS-induced spinal neuron degeneration after acute traumatic spinal cord injury. Life Sci 2006; 79: 1895-905.
35.
Ding D, Xu H, Liang Q, Xu L, Zhao Y, Wang Y. Over-expression of Sox2 in C3H10T1/2 cells inhibits osteoblast differentiation through Wnt and MAPK signalling pathways. Int Orthop 2012; 36: 1087-94.
36.
Collins CS, Hong J, Sapinoso L, et al. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci USA 2006; 103: 3775-80.